Amgen and Allergan on Friday announced that the biosimilars Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns), which reference Roche cancer drugs Avastin (bevacizumab) and Herceptin (trastuzumab), respectively, are now available in the US. "As the first products from our collaboration with Amgen to be launched in the country, Mvasi and Kanjinti reinforce our ongoing dedication to providing patients with additional treatment options," said David Nicholson, chief R&D officer at Allergan.
The drugmakers stated that both biosimilars will have a 15% lower wholesale acquisition cost (WAC) than their reference treatments. In particular, Mvasi will be priced at a WAC of $677.40 per 100 mg and $2709.60 per 400 mg single-dose vial, while Kanjinti is being made available at $3697.26 per 420 mg multi-dose vial. The companies added that at launch, Mvasi will be priced 12% below Avastin's current average selling price, with Kanjinti carrying a 13% lower average selling price versus Herceptin.
Mvasi became the first cancer biosimilar in the US with its approval for multiple cancer types in 2017. Kanjinti was authorised by the FDA last month for breast and gastric cancer, marking the fifth approval of a biosimilar referencing Herceptin.
Meanwhile, shares in Biocon fell nearly 8.2% on news of Kanjinti's entry into the US market. The Indian drugmaker's partner Mylan, received FDA approval of Herceptin biosimilar Ogivri (trastuzumab-dkst) in 2017, although Ogivri has not yet been launched in the US due to a licensing agreement between Mylan and Roche. The Swiss drugmaker has also been seeking a preliminary injunction to prevent Amgen and Allergan from launching Kanjinti.
Roche recorded CHF 1.8 billion ($1.8 billion) in first-quarter sales of Avastin, while Herceptin revenue totalled CHF 1.7 billion ($1.7 billion).
To read more Top Story articles, click here.